Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

October 23, 2023

Study Completion Date

October 23, 2028

Conditions
Human Immunodeficiency Virus (HIV)AIDS Virus
Interventions
BIOLOGICAL

A244

Dose of A244 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

BIOLOGICAL

B.63521

Dose of B.63521 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

BIOLOGICAL

50μg ALFQ

Dose of ALFQ is 50μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

BIOLOGICAL

100μg ALFQ

Dose of ALFQ is 100μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

BIOLOGICAL

200μg ALFQ

Dose of ALFQ is 200μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

Trial Locations (1)

20910

RECRUITING

Walter Reed Army Institute of Research, Clinical Trials Center, Silver Spring

All Listed Sponsors
collaborator

US Military HIV Research Program

NETWORK

collaborator

Henry M. Jackson Foundation for the Advancement of Military Medicine

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

U.S. Army Medical Research and Development Command

FED